CD274 and non-small cell lung carcinoma: Ideally, for patients with metastatic NSCLC, efforts should be directed towards targeted therapy or immunotherapy, however, there are instances where patients may not qualify for targeted or immunotherapies due to the absence of driver mutations or the unavailability of drugs, along with contraindications to PD-1 or PD-L1 inhibitors.